AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUL 102 min read$BCDA

Altman Peter purchased $7K of BCDA

Altman Peter (President and CEO) purchased 7,500 shares of BioCardia, Inc. (BCDA) at an average of $0.96 ($0.90–$0.97) across 3 trades over 2026-07-08 to 2026-07-10.

Original reporting
SEC EDGAR · Altman Peter
Published Jul 10, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 8:06 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$BCDA
Bullish
medium confidence
Mentioned
$BCDA
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BCDABullishLow
01

Why it matters

The newest fact is the disclosed open-market purchase of 7,500 shares across three trades between 2026-07-08 and 2026-07-10, totaling $7,175.

02

Market read

Traders may view the filing as a small bullish sentiment datapoint, but it lacks fundamental catalysts and is unlikely to drive sustained repricing alone.

03

What to watch

The article notes no 10b5-1 plan and provides only transaction details, not rationale, timing constraints, or whether other insiders are buying/selling.

Relevance 4/10Novelty 3/10Timing: filed 2026-07-10, covers purchases from 2026-07-08 to 2026-07-10

Background

This is an SEC Form 4 insider transaction for BioCardia, Inc., reported by CEO Peter Altman.

Company-level read

Ticker impact

$BCDABullishMedium confidence
Context

BioCardia CEO Peter Altman filed a Form 4 open-market purchase of 7,500 shares at about $0.9567 weighted average.

Expected impact

Likely limited near-term impact; any effect is sentiment-driven and typically fades unless followed by larger disclosures.

Evidence & confidence

The filing is a primary-source insider transaction, but the disclosed size ($7,175) is small and the article provides no new operational or financial information.

Market effects

Sector

No clear sector read-through from a small CEO open-market buy without accompanying company-specific fundamentals.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Insider buys can be routine liquidity or diversification-related and do not necessarily reflect near-term business improvement.

Key entities

  • issuer
    BioCardia, Inc.

    Company whose CEO insider transaction is disclosed on Form 4.

  • insider
    Altman Peter

    President and CEO reporting the open-market purchase.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

BCDA insider trading history →

Related articles

OCT 19
$BCDAMedAI 8/10

BioCardia Advances Helix Catheter Toward FDA Marketing Clearance

BioCardia (BCDA) submitted a revised De Novo pre-submission package to the FDA for its Helix catheter, following feedback. The FDA accepted the submission and expects review, feedback, and a meeting in Q4 2026. The catheter is designed for delivering therapeutic agents to heart muscle and has clinical safety data from 15 trials. FDA clearance could expand partnership opportunities for BCDA.

rttnews.com2 min
OCT 19
$BCDAHighAI 8/10

BioCardia: FDA Accepts De Novo Pre-Submission for Helix Catheter; Substantive Review, Meeting Expected This Quarter

BioCardia's FDA pre-submission for Helix catheter was accepted, with substantive review and a meeting expected this quarter. The FDA raised no concerns about safety or performance. The company has clinical data from 15 trials supporting potential clearance, which could expand partnerships. According to the company, marketing clearance could enhance opportunities with cardiac biologics developers.

tradingview.com1 min
OCT 19
$BCDAMedAI 8/10

FDA accepts BioCardia pre-submission for Helix catheter

BioCardia Inc. (BCDA) announced the FDA accepted its pre-submission for the Helix catheter, a device for heart agent delivery. The FDA indicated two pathways for clearance and raised no safety concerns. BioCardia expects substantive review and feedback this quarter. The Helix catheter is supported by clinical data from 15 trials with nearly 500 patients.

investing.com2 min
OCT 19
$BCDAHighAI 8/10

BioCardia Announces FDA Acceptance of De Novo Pre-Submission Package for HelixTM Catheter Marketing Clearance FDA Substantive Review and Meeting Expected…

BioCardia, Inc. (BCDA) filed an SEC Form 8-K — Other Events. Exhibit 99.1 BioCardia Announces FDA Acceptance of De Novo Pre-Submission Package for Helix TM Catheter Marketing Clearance FDA Substantive Review and Meeting Expected this Quarter October 19, 2026, Sunnyvale, Calif. BioCardia, Inc. [NASDAQ: BCDA] , a global leader in cellular an

SEC EDGAR 8-K2 min